Welcome to our dedicated page for Teleflex news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex stock.
Teleflex Incorporated (NYSE: TFX) is a leading global provider of specialty medical devices for critical care and surgical procedures. Headquartered in Wayne, Pennsylvania, Teleflex employs approximately 12,000 people worldwide and serves healthcare providers in more than 150 countries.
The company’s diverse product portfolio spans across several key segments: vascular access, interventional, anesthesia, surgical, interventional urology, original-equipment manufacturing, and others. These segments collectively cover a wide range of medical needs, from complex surgical interventions to everyday critical care requirements.
Teleflex’s vascular access segment, contributing 24% to 2023 sales, includes innovative solutions for secure and reliable bloodstream access. The interventional segment, accounting for 17%, focuses on cutting-edge devices for minimally invasive procedures. Anesthesia and surgical segments, with 13% and 14% of sales respectively, offer advanced tools and technologies to improve patient outcomes during surgeries.
The company’s interventional urology segment, noted for its UroLift™ System, addresses benign prostatic hyperplasia (BPH) with minimally invasive solutions that preserve patient quality of life. Original-equipment manufacturing and other segments contribute 11% and 10% of sales respectively, underscoring Teleflex’s broad manufacturing capabilities and diverse product offerings.
Teleflex's geographic exposure is primarily in the United States, which generates 60% of its revenue, with international markets contributing the remainder. The company’s global reach and diverse product lines highlight its significant impact on the healthcare industry worldwide.
In recent years, Teleflex has achieved notable success with a 6.5% constant currency revenue growth in 2023, driven by the expansion of its geographic presence and the launch of innovative new products. The company has strategically acquired Palette Life Sciences AB, enhancing its portfolio and operational efficiencies.
Teleflex remains committed to its mission of providing solutions that improve outcomes and enhance safety for patients and healthcare providers. By leveraging purpose-driven innovation, Teleflex continues to address unmet clinical needs and advance healthcare technologies.
For more information about Teleflex and its comprehensive product offerings, please visit teleflex.com.
Teleflex (NYSE: TFX) has announced its participation in the Raymond James & Associates 46th Annual Institutional Investors Conference. The event will take place at the JW Marriott Grande Lakes in Orlando, Florida, on Tuesday, March 4, 2025, at 3:25 p.m. (ET).
The company's management will deliver a presentation, which will be accessible to investors through a live audio webcast along with accompanying slides. Interested parties can access the presentation through the investor section of the Teleflex website at teleflex.com.
Teleflex (NYSE:TFX) has announced it will host a conference call to discuss its fourth quarter financial results and provide an operational update on Thursday, February 27, 2025, at 8:00 a.m. Eastern Time. Participants can pre-register to receive dial-in information, and the call will also be accessible via live audio webcast on teleflex.com.
An audio replay will be available starting at 11:00 am Eastern Time on the same day, accessible through the company's website or by telephone. The replay can be accessed by dialing 1 800 770 2030 (U.S. and Canada) or 1 609 800 9909 (other locations) with conference ID 69028.
Pulse Biosciences (PLSE) has appointed Jon Skinner as Chief Financial Officer, effective February 3, 2025. Skinner brings extensive healthcare sector experience, most recently serving as VP of FP&A and Investor Relations at Copeland. His prior roles include VP of Finance and Corporate Development at Imperative Care and VP of Finance – Interventional Urology at Teleflex, where he led 25 M&A transactions.
As part of his appointment, Skinner received inducement grants of options to purchase 300,000 shares at $20.93 per share. The options vest over four years, with half based on continuous employment and half tied to achieving product revenue and market capitalization milestones between $2 billion and $5 billion.
The appointment aims to support the company's operational excellence and commercialization of its CellFX nanosecond PFA Platform, which utilizes proprietary Nanosecond Pulsed Field Ablation technology.
Teleflex (NYSE: TFX) has secured a contract with Vizient, the largest provider-driven healthcare performance improvement company in the U.S., effective January 1, 2025. The agreement covers Teleflex's Central Venous Access Catheters and Arterial Catheters supply.
Vizient serves over 65% of U.S. acute care providers, including 97% of academic medical centers, representing more than $140 billion in annual purchasing volume. The contract enables Vizient provider-customers to access increased savings and pre-negotiated terms on Teleflex's vascular access products.
The agreement includes Arrowg+ard Blue Plus™ CVCs, which feature antimicrobial protection reducing Central Line-Associated Bloodstream Infections by 67-100%, Arrow™ ErgoPack™ Complete Systems, and Arrow™ Arterial Catheters and Catheterization Kits. These solutions help healthcare systems comply with practice recommendations, standardize vascular access products, and control infection-related costs.
Teleflex (NYSE: TFX) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's Chairman, President and CEO, Liam Kelly, will deliver a presentation at The Westin St. Francis in San Francisco, California, on Tuesday, January 14, 2025, at 5:15 p.m. (PT).
Investors and interested parties can access a live audio webcast of the presentation along with accompanying slides through the investor section of the Teleflex website at teleflex.com.
Teleflex (NYSE: TFX) announced its participation in the 36th Annual Piper Sandler Healthcare Conference. Liam Kelly, Chairman, President and CEO, will present at The Lotte New York Palace on Tuesday, December 3, 2024, at 9:30 a.m. (ET). Investors can access a live audio webcast of the presentation through the investor section of the Teleflex website.
Teleflex (NYSE: TFX) announced that Chairman, President and CEO Liam Kelly will present at the Jefferies London Healthcare Conference on Thursday, November 21, 2024, at 9:30 a.m. GMT. The presentation will be accessible via live audio webcast through the investor section of the Teleflex website at teleflex.com.
Teleflex (NYSE: TFX) has announced a quarterly cash dividend of $0.34 per share of common stock. The dividend will be paid on December 16, 2024, to shareholders who are on record as of the close of business on November 15, 2024.
Teleflex (TFX) reported Q3 2024 financial results with GAAP revenue of $764.4 million, up 2.4% year-over-year. The company lowered its full-year 2024 GAAP revenue growth guidance to 2.90%-3.40% from previous 3.40%-4.40%. GAAP diluted EPS from continuing operations was $2.36, compared to $2.91 in prior year. Adjusted diluted EPS was $3.49 versus $3.64 last year. Strong performances in Interventional and Vascular Access segments helped offset weakness in OEM revenues. The company announced a $500 million share repurchase authorization, including a $200 million accelerated share program in Q3.
Teleflex (NYSE: TFX) announced enrollment of the first patient in the PPRT Trial, a randomized controlled study evaluating the Barrigel™ rectal spacer in patients undergoing radiation therapy after prostatectomy. The study aims to demonstrate the safety and effectiveness of Barrigel™, the first sculptable hyaluronic acid rectal spacer, in reducing radiation side effects.
The trial will be conducted across sites in the U.S. and Australia, focusing on patients who have undergone nerve-sparing prostatectomy with no evidence of metastatic disease. Barrigel™'s unique properties allow physicians to sculpt and optimize rectal protection during radiation therapy, remaining soft and pliable unlike other spacers that harden immediately after administration.
FAQ
What is the current stock price of Teleflex (TFX)?
What is the market cap of Teleflex (TFX)?
What does Teleflex Incorporated do?
Where is Teleflex Incorporated headquartered?
How many people does Teleflex employ?
What are the main segments of Teleflex's business?
What percentage of Teleflex’s revenue comes from the United States?
What recent acquisitions has Teleflex made?
What is the UroLift™ System?
What was Teleflex's revenue growth in 2023?
How can one access Teleflex's investor conference calls?
What is the mission of Teleflex Incorporated?
